---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006837"
form_type: "8-K"
ticker: "BRTX"
cik: "0001505497"
company_name: "BioRestorative Therapies, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:24:22.894958+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs

## Summary
- Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.
- Gross proceeds ~$5.0M net of ~7% placement agent fee and expenses.
- Proceeds to fund BRTX-100 Phase 2 trial, ThermoStem R&D, biocosmeceuticals platform, and working capital.
- Rodman & Renshaw acted as exclusive placement agent; 90-day lockup on new equity issuances.

## SEC filing metadata
- accession: 0001493152-26-006837
- form_type: 8-K
- ticker: BRTX
- cik: 0001505497
- company_name: BioRestorative Therapies, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/0001493152-26-006837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006837
- JSON: https://secwatch.observer/filing/0001493152-26-006837.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006837.txt

## Key facts
- Material Agreements
  BioRestorative Therapies, Inc. entered into Securities Purchase Agreement with certain institutional investors (effective 2026-02-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Effective: 2026-02-11
  source text: On February 11, 2026, BioRestorative Therapies, Inc. (the “Company”) commenced a public offering (the “Offering”) of an aggregate of (a) 12,560,715 units (the “Common Units”), consisting of (i) 12,560,715 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) five-year warrants to purchase up to 12,560,715 shares of Common Stock (the “Common Stock Warrants”), at an offering price of $0.35 per Common Unit, and (b) 1,725,000 units (the “Pre-Funded Units”), consisting of (i) pre-funded warrants to purchase up to 1,725,000 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) five-year warrants to purchase up to 1,725,000 shares of Common Stock, at an offering price of $0.3499 per Pre-Funded Unit.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505497/000149315226006837/0001493152-26-006837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.